NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar…
NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – Compared with midazolam or propofol for sedation during prolonged mechanical ventilation, dexmedetomidine offers advantages in terms of improved patients’ interaction with ICU staff…
NEW YORK (Reuters Health) – The lipid-modifying effects of rosuvastatin (Crestor: AstraZeneca) are stronger than atorvastatin (Lipitor; Pfizer) in patients with an acute coronary syndrome (ACS), according to…
NEW YORK (Reuters Health) – The benefit of renin-angiotensin system inhibition in systolic heart failure (HF) extends to older patients with chronic kidney disease (CKD), a new study…
NEW YORK (Reuters Health) – A new analysis of pooled data on omalizumab should help allay concerns that omalizumab (Xolair; Genentech, Novartis) may increase the risk for cancer.…
NEW YORK (Reuters Health) – Pain associated with acute renal colic is relieved more effectively when intravenous papaverine is added to treatment with diclofenac suppository, an Iranian team…
NEW YORK (Reuters Health) – Increases in fasting blood sugar levels are often seen in patients starting niacin, sometimes to a level that suggests new onset of type…
NEW YORK (Reuters Health) – Avanafil, another phosphodiesterase type 5 (PDE5) inhibitor, improves sexual function in men with erectile dysfunction, according to a report in the January 16th…
NEW YORK (Reuters Health) – There is no need to avoid proton pump inhibitors (PPIs) in patients on the platelet inhibitors clopidogrel or ticagrelor. The increased rates of…